Αρχική World News EMA Recommends Extension of Indications for Pirtobrutinib World News EMA Recommends Extension of Indications for Pirtobrutinib Από Ogkologos - 24 Απριλίου, 2025 962 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Researchers Create Modified Antibodies to Target RAS and p53 in Cancer 2 Απριλίου, 2021 FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... 20 Νοεμβρίου, 2024 How People With Cancer Can Make the Most of Televisits 4 Δεκεμβρίου, 2020 Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in... 16 Δεκεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer Woman Helps Students With Special Needs Achieve Success After Graduation Reassuring Results Observed with Shorter Duration of Adjuvant Trastuzumab in HER2-positive... FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC